CDC7-DBF4 kinase (DDK) is required to initiate DNA replication in eukaryotes by activating the replicative MCM helicase. DDK has also been reported to have diverse and sometimes conflicting roles in the replication checkpoint response in various organisms but the underlying mechanisms are far from settled. Here we show that human DDK promotes limited resection of newly synthesized DNA at stalled replication forks or sites of DNA damage to initiate replication checkpoint signaling. DDK is also required for efficient fork restart and G2/M cell cycle arrest. DDK exhibits genetic interactions with the ssDNA exonuclease EXO1, and we show that EXO1 is also required for nascent strand degradation following exposure to HU, raising the possibility that DDK regulates EXO1 directly. Thus, DDK has a primary and previously undescribed role in the replication checkpoint to promote ssDNA accumulation at stalled forks, which is required to initiate a robust checkpoint response and cell cycle arrest to maintain genome integrity.
DDK is a two-subunit kinase that is essential to initiate DNA replication at individual replication origins by phosphorylating and activating the MCM2-7 replicative helicase. The regulatory subunit DBF4 binds to CDC7 and is required for its kinase activity [1] . DDK also has roles in replication checkpoint signaling that are less well understood [1] . In budding yeast, DDK is a target of the checkpoint effector kinase Rad53 that is activated following replication stress [2] . Rad53-mediated phosphorylation of Dbf4 modestly reduces DDK activity [2] and also inhibits late origin firing [3, 4] , but there is also evidence that DDK is required for the complete activation of Rad53 kinase [5] . In fission yeast, DDK subunits Hsk1 and Dfp1 are phosphorylated upon HU treatment by the checkpoint kinase Cds1, orthologous to budding yeast Rad53 and mammalian CHK2 [6] [7] [8] . Deletion of either Cds1 or its activating protein Mrc1 partially rescues the temperature sensitivity of hsk1-1312 mutants suggesting that Cds1 (like Rad53) inhibits DDK activity [8, 9] . Cds1 activation in response to HU, however, was reduced significantly in hsk1(ts) strains at restrictive temperature and the cell cycle arrest was also aberrant as seen by an increased population of 'cut' cells (indicative of mitosis without complete DNA replication) [8, 10] . These paradoxical results in yeast could be explained by a negative feedback loop where DDK first helps to initiate replication checkpoint activation and then the checkpoint pathway subsequently alters DDK activity to inhibit late origin firing.
Initial studies in human cells showed that the replication checkpoint inhibits DDK activity, presumably to inhibit origin firing [11, 12] . However, subsequent studies reported that human DDK is active during replication stress and has an upstream role to fully activate the checkpoint kinase CHK1 [13, 14] . In response to exogenous replication inhibitors, DDK recruitment to chromatin is increased [13, 14] , CDC7-DBF4 complex is stabilized [13] , and MCM shows increased phosphorylation at several DDK-specific sites [13, 15] . DDK promotes CHK1 phosphorylation partly through binding to and phosphorylating Claspin, an adaptor protein required for CHK1 activation [16, 17] . Although depleting the CDC7 protein subunit using a CDC7 siRNA resulted in loss of chromatin-bound Claspin following HU treatment [16] , inhibiting DDK activity using small molecule inhibitors did not [17] . Furthermore, depleting Claspin using siRNA did not reduce CHK1 phosphorylation to the same extent as CDC7 siRNA [16] , suggesting that DDK could promote checkpoint signaling by other mechanisms. In this study, we show that DDK has a primary role to initiate checkpoint signaling by promoting ssDNA formation at stalled forks, most likely by promoting nascent DNA resection.
Results and Discussion

DDK has a primary role in initiating replication checkpoint signaling
Since blocking DDK activity largely prevents CHK1 phosphorylation upon exposure to replication stress [14, 16, 17] , we analyzed how DDK influences the overall checkpoint response induced by HU. We found that 5 µM of DDKi and a pre-treatment time of 4 hours were required to substantially block CHK1 activation by HU in HCC1954 cells (Supplementary Figure 1A) . HCC1954 is a breast cancer cell line that expresses high levels of both DDK subunits and exhibits robust decrease in MCM2 phosphorylation in response to the prototype DDK inhibitor, PHA-767491 (DDKi) [18] . As shown previously, CHK1 activation was almost completely eliminated by pre-treatment with the DDK inhibitor PHA-767491 ( Figure 1A) . A similar effect on CHK1 activation was seen in response to the more specific DDK inhibitor XL413 in Colo-205 cells ( Figure 1B ). However unexpectedly, we found that RPA2 phosphorylation and chromatin accumulation following HU exposure were also significantly reduced if DDK activity was blocked ( Figure 1A, B) . This is not consistent with a singular role for DDK to promote CHK1 activation through Claspin phosphorylation. We saw an identical decrease in RPA2 phosphorylation and chromatin accumulation when DDK activity was blocked using an siRNA against CDC7 (Supplementary Figure 1B) . Chromatin-bound RPA2 immunofluorescence, which is sharply increased after 2 hours of HU exposure, was also significantly reduced in CDC7 siRNA-treated cells Figure 1C) . DDK inhibition also prevented CHK1 phosphorylation, RPA2 accumulation and RPA2 phosphorylation in response to two DNA damaging agents, camptothecin and etoposide (Supplementary Figure 1D, E) . Using a non-denaturing BrdU assay that directly measures ssDNA formation we found that the ssDNA formation upon HU treatment was significantly reduced upon DDK inhibition ( Figure 1C) . DDK inhibition alone, in the absence of exogenous replication inhibitors, did not result in widespread ssDNA formation nor the activation of replication-checkpoint signaling Figure 2A, B) confirming several earlier findings [19, 20] . RPA2 S33 was mildly phosphorylated in response to the DDK inhibitor as opposed to hyperphosphorylation observed upon replication stress [21] . Taken together, our results show that DDK inhibition substantially blocks the accumulation of ssDNA and downstream events (i.e., RPA binding to ssDNA) in response to replication fork stalling by HU or DNA damage by camptothecin and etoposide.
(Supplementary
While reduced origin firing upon DDK inhibition might explain the lack of checkpoint activation in response to HU, several pieces of evidence argue against this and suggest a more direct role for DDK at stalled forks. Firstly, inhibition of ATR kinase in unperturbed cells induces aberrant origin firing leading to accumulation of chromatin-bound RPA1 and RPA2 ( Figure 1D , lane 3 vs. 15) [22, 23] . This RPA accumulation, however, was prevented upon co-treatment with DDKi ( Figure 1D , lane 15 vs. 18) consistent with the essential role of DDK in origin firing. In contrast, HU-mediated RPA accumulation on chromatin, which is blocked by prior treatment with DDKi, was not affected by co-treatment with DDKi ( Figure 1D , lane 9 vs. 12). In fission yeast hsk1-89 temperature sensitive strain that alters the Cdc7 subunit showed ~20-fold reduction in Cds1 (Rad53/CHK2) activation following HU treatment, even at permissive temperature [10] . Other fission yeast mutants defective in origin firing (e.g., mcm4 or orc1 mutants) did not show a similar reduction in Cds1 activation [10] , suggesting an origin-independent role for Hsk1 (CDC7) in Cds1 activation. Budding yeast cdc7 and dbf4 mutants also have substantially reduced levels of Rad53 [24] . These results suggest that DDKi-mediated reduction in origin firing per se does not significantly affect the extent of checkpoint activation and ssDNA at stalled forks.
We also found that overexpressing human DDK subunits increased the phosphorylation of CHK1 and RPA2 in response to HU treatment ( Figure 1E ), again consistent with a positive role for DDK in promoting checkpoint activation. In summary, our results indicate that DDK promotes formation of ssDNA-RPA complexes upon exposure to various forms of replication stress independently of its role in origin activation. This was confirmed below using single molecule analyses.
DDK is required for processing stalled replication forks
Based on the findings described above, we hypothesized that DDK is required to process stalled replication forks to activate the replication checkpoint. To test our hypothesis, we performed DNA fiber analysis and measured the effect of inhibiting DDK at established forks with or without HU treatment Figure 4B ) and several studies have shown that collapse of stalled forks only occurs after prolonged (12 to 24hr) exposure to HU [27, 28] . Therefore, nascent strand degradation seen after 2h of HU exposure is likely to be a physiological response. In a Xenopus in vitro system, aphidicolin treatment, which inhibits DNA polymerase alpha and delta, results in unrestricted DNA unwinding and ssDNA formation ahead of the stalled fork that is thought to induce the replication checkpoint [29] . This was proposed to be due to a functional (but not physical) uncoupling of the replicative polymerases and helicase (see model in Figure 5 ). Given that helicase and polymerase activities are strongly interdependent and depend on physical interactions in many model organisms [30] [31] [32] , it is not clear how a functional uncoupling might result in independent helicase activity in living cells. Electron microscopic analysis has shown that ssDNA formed in yeast at stalled forks is limited to one parental strand [33, 34] . However, uncoupling between the polymerase and helicase would generate long ssDNA on both leading and lagging strands. In addition, diverse types of replication inhibitors generate ssDNA, even inter-strand crosslinking agents, which would not allow helicase activity or polymerase activity beyond the crosslink [35] . So, while helicase-polymerase uncoupling can generate ssDNA ahead of the forks in response to certain types of replication stress, our data suggest that DDK-dependent limited processing of nascent DNA behind stalled forks might be a more universal mechanism for ssDNA formation.
DDK is required for restart of stalled replication forks:
An important function of the replication checkpoint pathway is to promote DNA repair mechanisms required for rescuing and restarting stalled forks [1] . Using a DNA fiber assay, we measured the rate of fork restart following 1 or 2 hours of CPT exposure ( Figure 2C ). If DDK is required for fork restart, we would expect to see a reduced rate of fork restart in CPT+DDKi treated cells compared to CPT treatment alone. Sixty-four percent of forks restarted after 1h of 1 µM CPT exposure and this was reduced to 46% when cells were pre-treated with DDKi for 4 hours ( Figure 2D ). The effect of 2 hours of CPT on fork restart was more severe with only 40% of forks restarting after removal of CPT. This was further reduced to 27% when they were pre-treated with DDKi for 4 hours ( Figure 2E ). These results confirm that DDK is required for efficient replication fork restart, presumably because cells are defective in initiating the replication checkpoint and DNA repair and therefore cannot efficiently restart stalled replication forks.
DDK likely promotes fork processing by regulating the activity of nucleases at stalled forks
To identify potential nucleases and helicases required for processing replication forks after 2 hours exposure to HU, we used siRNAs to knock down enzymes known to act on collapsed forks plus those identified at unperturbed and stalled replication forks through iPOND analysis [36] [37] [38] . Knockdown of EXO1, BLM, and CtIP reduced phospho-CHK1 levels in response to HU whereas MRE11 knockdown did not ( Figure 3A and Supplementary Figure 4A) . Knockdown of these enzymes did not significantly affect cell cycle profiles (Supplementary Figure 4B) . EXO1 knockdown showed the strongest effect on CHK1 phosphorylation. Moreover, in HEK-293 cells EXO1 knockdown significantly reduced ssDNA formation after 2h of HU treatment [39] . We did not observe a reduction in RPA2-S4/S8 phosphorylation upon knockdown of any of the potential resection enzymes. It has been suggested that the initial resection at stalled forks is independent of regression of nascent DNA at stalled forks, which could be the signal for RPA2-S4/S8 phosphorylation [28] . Consistent with this, knockdown of the fork regression helicase FBH1 resulted in a decrease in RPA2-S4/S8 phosphorylation after a short HU treatment but had no effect on ATR-CHK1 signaling [28] . Since DDK inhibition results in significant reduction in both CHK1 and RPA2 phosphorylation, this further argues for an upstream role for DDK in replication checkpoint activation.
EXO1 exists in a complex with EEPD1, BLM, and RPA and knockdown of individual proteins destabilizes other proteins in the complex [40] . Interestingly, EXO1 and BLM are significantly less abundant following exposure to DDKi with or without exposure to DNA damaging agents ( Figure 3B , bottom panels). Moreover, knocking down either CDC7 or EXO1 significantly reduced expression of the other protein ( Figure 3C ). Destabilization of EXO1 could be rescued by treatment with the proteasome inhibitor MG-132, indicating that EXO1 is actively degraded post-transcriptionally in the absence of DDK activity ( Figure 3D ). In contrast, CtIP stability was only slightly reduced upon DDK inhibition and the levels of MRE11 were unchanged ( Figure 3B ). This data shows that DDK is required for EXO1 and BLM stability and therefore activity, and further suggests an important role for the EXO1-BLM complex in fork resection immediately after fork stalling. 
Low dose DDKi causes aberrant mitotic structures
While untransformed human cells prevent S-phase progression upon DDK inhibition by inducing a G1/Scheckpoint [19, 42] , tumor cells proceed through an aberrant S-phase and undergo apoptosis but the exact mechanism that triggers apoptosis remains unknown [19, 20] . Inhibiting DDK during S-phase will reduce the number of overall replication forks and inhibit restart of stalled forks (shown here) leading to incomplete DNA replication and a G2/M arrest. However, DDKi-treated cells are also significantly defective in checkpoint activation and therefore would have difficulty restraining mitosis. Our findings therefore prompted us to examine mitotic progression in HCC1954 cells using a low dose of DDKi that will allow S-phase progression. Strikingly, we found numerous aberrant mitotic figures in the DDKitreated cells similar to cells treated with a low dose (0.4µM) of aphidicolin, which is known to slow DNA polymerization and induce mitotic abnormalities [43, 44] (Figure 4A ). The defects in mitosis observed after 24-hour treatment with 1µM DDKi (PHA) were not a by-product of apoptosis as the same effect was seen both with and without co-treatment with the pan-caspase inhibitor zVAD. To confirm that this effect is DDK-specific we also tested the more selective biochemical DDK inhibitor, XL413 [45] . In HCC1954 cells and many other cell lines, XL413 is a poor in vivo inhibitor of DDK activity and has little effect on cell growth even at high inhibitor concentrations [18] . We therefore used relatively high 10µM and 20µM concentrations of XL413 to moderately inhibit DDK in HCC1954 cells but not induce apoptosis. We found that XL413 treatment also significantly increased the number of mitotic abnormalities in a dosedependent manner confirming this to be a DDK-specific phenotype ( Figure 4A ). Although the increase in lagging chromosomes was similar in aphidicolin and DDKi-treated cells, DDKi treatment resulted in higher number of anaphase bridges compared to aphidicolin-treated cells. Anaphase bridges are thought to arise from chromosomes that have long stretches of incompletely replicated DNA, fused telomeres, or chromatid cohesion defects [46] . Our data suggest that low-level DDKi-treated cells undergo mitosis in presence of under-replicated DNA. Correspondingly, cell cycle arrest by HU pretreatment rescued cell death induced by DDKi and the extent of rescue was positively correlated with increasing time in HU, with 24 hours of HU pre-treatment showing the strongest rescue (Figure 4B, C) . Inhibition of CHK1 activation using a specific CHK1 inhibitor (LY2603618) did not abrogate the rescue seen upon HU pretreatment ( Figure 4D, E) . Therefore, preventing S-phase or fork progression protects cells against apoptosis upon DDK inhibition, but active CHK1 is not sufficient for this protection.
Fission yeast cells with hypomorphic DDK mutations also exhibited defective mitosis and DNA fragmentation [8, 10] . Importantly, these mutations are synthetically lethal with mutation in the cohesin protein rad21 [8, 10] . These findings have led to the suggestion that DDK has a role in maintaining sister chromatid cohesion following DNA replication. The lack of checkpoint-induced cell cycle arrest, inability to restart naturally stalled forks, and compromised sister chromatid cohesion might explain the severe mitotic abnormalities seen in an asynchronous population of HCC1954 cells with reduced DDK activity.
In summary, we propose that ssDNA generated upon fork stalling is primarily a result of nascent strand degradation that requires DDK ( Figure 5 ). DDK is therefore required for the initiation of replicationcheckpoint activation, and we also show for the recovery of stalled forks. An active replicationcheckpoint would then attenuate nucleolytic activity at stalled forks to prevent excessive degradation of DNA by described mechanisms [41, [47] [48] [49] . Budding yeast cells lacking the checkpoint kinase Rad53, which inhibits DDK, exhibited extremely long tracks of ssDNA in presence of replication stress, which were abrogated upon deletion of Exo1 [33] again consistent with our model. Our analysis of EXO1 further shows that it plays a critical role in nascent strand degradation following exposure to HU and that 
Materials and Methods
Cell lines and reagents
HCC1954 cells (ATCC) and Colo-205 (NCI-60) were cultured in RPMI-1640 media supplemented with 10% heat inactivated (HI) FBS, 50units/ml of penicillin, and 50µg/ml of streptomycin. The DDK inhibitors, PHA-767491 and XL413, were synthesized as described previously [18] . ATR inhibitor (VE-821, #A2521) and Camptothecin (#A2877) was from APExBIO. CHK1 inhibitor (LY2603618, #S2626) was from Selleckchem. Etoposide (#341205) was from EMD Millipore. Hydroxyurea (#H9120) was from USBiological. The antibodies were purchased as indicated: CST: PARP (#9542), pCHK1 S317 (#12302), pCHK1 S345 (#2348), pCHK1 S296 (#2349), CHK1 (#2360), pCHK2 T68 (#2197), CHK2 (#6334), RAD51 (#8875), CtIP (#93110), RECQL4 (#2814); Bethyl Laboratories Inc.: pMCM2 S53 (A300-756A), pMCM2 S108 (A300-094A), MCM2 (A300-122A), pRPA2 S33 (A300-246A), pRPA2 S4/S8 (A300- 
Immunoblotting and protein fractionation:
Whole cell extracts were prepared by re-suspending the pellets in RIPA buffer (150mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, 50mM Tris-HCl, pH 8) containing protease inhibitors (100µM PMSF, 1mM Benzamidine, 2.5µg/ml Pepstatin A, 10µg/ml Leupeptin, and 10µg/ml Aprotinin) and phosphatase inhibitors (1mM each NaF, Na 3 VO 4 , Na 2 P 2 O 7 ). Protein concentration was measured using the BCA protein assay kit (Pierce, #23227). Cell fractionation into cytosolic, nuclear soluble, and nuclear insoluble (chromatin) fractions was performed as described previously [50] . Pellets were re-suspended in lysis Buffer A (10mM HEPES (pH 7.9), 10mM KCl, 1.5 mM MgCl 2 , 0.34M Sucrose, 10% Glycerol, 1mM DTT, and protease and phosphatase inhibitors) and Triton X-100 was added to a final concentration of 0.1%. After incubation on ice for 8min, lysates were centrifuged at 1,300g, at 4 0 C, for 5min. The supernatant was collected and clarified by high-speed centrifugation (20,000g, 4 0 C, 5min) to obtain cytosolic fraction. The pellet was washed once with Buffer A and then lysed in Buffer B (3mM EDTA, 0.2 mM EGTA, 1mM DTT, protease and phosphatase inhibitors) for 30min on ice. Soluble nuclear fraction (supernatant) was collected by centrifugation at 1,700g, at 4 0 C, for 5min. The chromatin fraction (pellet) was washed once with Buffer B, re-suspended in Buffer B, and sonicated briefly. Protein concentration in each fraction was measured using Bradford assay (Bio Rad, #500-0006). Equal amounts of proteins were subjected to SDS-PAGE and transferred to nitrocellulose membrane (Millipore, HATF304F0). Transfer efficiency and equal loading was confirmed by Ponceau S staining. Membranes were blocked overnight at 4 0 C with 5% non-fat milk in TBS-T, followed by incubation in primary and secondary antibodies (1h at RT, 2% milk in TBS-T). Protein bands were visualized using SuperSignal
West Pico solutions (Thermo Scientific).
Analysis of Caspase 3/7 activity:
5000 cells per well were plated in 96 well plates. 24 hours later cells were treated and incubated for the indicated period of time at 37 0 C. Caspase 3/7 activity and viable cell number were then measured using the Caspase-Glo 3/7 assay (Promega) and CellTiter-Glo assay (Promega), respectively. The 'caspase activity per cell' was obtained by normalizing total caspase activity to cell number. Luminescence was measured using BioTek Synergy Microplate Reader 30 minutes after addition of 'Glo' reagents.
Cell Cycle Analysis:
Cells were trypsinized, washed twice with cold PBS, and fixed/permeabilized in 70% ice-cold ethanol (made in water). After fixation on ice for 30mins cells were centrifuged at 400g (4 0 C, for 5mins), washed once with cold PBS, and centrifuged again. The pellets were re-suspended in analysis buffer (10µg/ml propidium iodide and 250µg/ml RNAase) and incubated at 37 0 C for 30min. Cell cycle profiles were obtained using FACSCalibur TM (BD Biosciences) flow cytometer. The data was analyzed using Flowing Software.
Immunofluorescence:
HCC1954 cells were seeded at 50,000 to 70,000 cells per well on number 1.5 coverglass in 24-well tissue culture dishes. siRNA-mediated knockdown was carried out in 6-well plates. 24 hours later the cells were trypsinized and re-plated on coverglass in 24-well plates. After 36 hours, cells were treated as indicated. DMEM + 10%FBS + 0.01% sodium azide) for 1h followed by 3 washes with PBS-T. Nuclear DNA was stained with Hoechst 33342 (2 µg/ml). Coverglass was inverted onto microscope slides using mounting gel. Cells were imaged using a 60X oil-immersion objective on a Nikon Eclipse Ti florescent microscope.
Image processing and quantification were completed with NIS Elements software (Nikon). To quantify, regions of interest (ROI) were drawn around each nucleus. Using HU-treated cells as a positive control, intensity thresholds (binary) were set to include all pixels equal to or greater than the intensity of the background 488 fluorescence. The binary was applied to all samples and the sum intensity of the 'binary in ROI' was calculated for each nucleus. All values were normalized to the mean intensity of the vehicle control. For analysis of mitotic abnormalities, cells were fixed and permeabilized in 70% ethanol. Nuclear DNA was stained with Hoechst 33342 (2ug/ml). Image analysis was performed using NIS Elements software (Nikon). Statistical analysis was performed using Graph Pad Prism.
DNA fiber spreading
DNA fiber spreading was performed as described previously [51, 52] . Briefly, sub-confluent cells were sequentially labeled first with 10 µM 5-iodo-2'-deoxyuridine (IdU) and then with 100 µM 5-chloro-2'-deoxyuridine (CldU) for the indicated times. One thousand cells were loaded onto a glass slide (Star Frost) and lysed with spreading buffer (200 mM Tris-HCl pH 7.5, 50 mM EDTA, 0.5% SDS) by gently stirring with a pipette tip. The slides were tilted slightly and the surface tension of the drops was disrupted with a pipette tip. The drops were allowed to run down the slides slowly, then air-dried, fixed in methanol/acetic acid 3:1 for 10 minutes, and allowed to dry. Glass slides were processed for immunostaining with mouse anti-BrdU to detect IdU (347580, BD Biosciences), rat anti-BrdU (ABC117- 
